Rapport Therapeutics, Inc. (RAPP)
41.95
+0.56
(+1.35%)
USD |
NASDAQ |
Sep 17, 16:00
41.92
-0.03
(-0.08%)
Pre-Market: 20:00
Rapport Therapeutics Shareholders Equity (Quarterly) : 422.93M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 422.93M |
| March 31, 2026 | 471.51M |
| December 31, 2025 | 484.65M |
| September 30, 2025 | 511.62M |
| June 30, 2025 | 263.51M |
| March 31, 2025 | 285.84M |
| Date | Value |
|---|---|
| December 31, 2024 | 305.43M |
| September 30, 2024 | 323.11M |
| June 30, 2024 | 336.89M |
| March 31, 2024 | 195.11M |
| December 31, 2023 | 140.94M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 597.21M |
| Corcept Therapeutics, Inc. | 705.78M |
| Veru, Inc. | 28.38M |
| Johnson & Johnson | 84.97B |
| Eli Lilly & Co. | 33.88B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 458.98M |
| Total Liabilities (Quarterly) | 36.06M |
| Debt to Equity Ratio | 0.0239 |
| Current Ratio | 15.72 |
| Net Debt Paydown Yield | -0.02% |